-
Rocilinostat (ACY-1215) Assay Workflow Guide
2026-08-13
Build more informative HDAC6 experiments with Rocilinostat (ACY-1215), combining α-tubulin acetylation, viability, apoptosis, and combination-response readouts. The workflow also translates a sphingolipid–cilia discovery into a carefully bounded assay concept for neural progenitor research.
-
Early Pheromone Sensing and Neurodegeneration in C. elegans
2026-08-13
Peng et al. show that pheromone perception during the L1 developmental stage can remodel neural development and accelerate adult neurodegeneration in C. elegans. Their mechanistic model connects ASK and ASI sensory neurons with AIA interneurons, insulin-like signaling, and neuronal autophagy, offering a framework for studying how early environmental cues influence later proteostasis failure.
-
Carfilzomib Sensitizes ESCC to Iodine-125 Radiation
2026-08-12
The reference study shows that Carfilzomib amplifies iodine-125 seed radiation responses in esophageal squamous cell carcinoma by intensifying endoplasmic reticulum stress and activating apoptosis, paraptosis, and ferroptosis. Its main practical implication is a mechanistically broad radiosensitization strategy that should be evaluated with coordinated proteostasis, cell-death, and in vivo tolerance assays.
-
From Pheromone Signals to Precise Neurogenetics
2026-08-12
Peng et al.’s C. elegans study shows how early pheromone perception can remodel neurodevelopment and accelerate adult neurodegeneration. This thought-leadership analysis connects that mechanistic framework to sequence-accurate PCR strategy, positioning HyperFusion™ high-fidelity DNA polymerase for robust genotyping, cloning, and sequencing workflows without overstating preclinical evidence.
-
Rocilinostat: HDAC6 Biology Meets Assay Design
2026-08-11
Rocilinostat (ACY-1215) is a selective HDAC6 inhibitor that can do more than reduce myeloma growth signals. This article connects its mechanism to a rigorous, multi-readout assay strategy informed by new findings on SMPD4, ceramide, neural progenitor survival, and primary cilia.
-
Oligo (dT) 25 Beads for Goose Muscle RNA-Seq
2026-08-11
Oligo (dT) 25 Beads provide selective polyA-tail capture for eukaryotic mRNA isolation. This guide connects bead-based sample preparation with the transcriptome–metabolome design used to study goose muscle biology, helping researchers make better assay and library decisions.
-
CXCR4 Theranostics in Lymphoma: Evidence and Limits
2026-08-10
This 2026 review presents CXCR4 as a theranostic target in lymphoma, linking receptor-directed PET or SPECT imaging with precision treatment strategies. Its main contribution is an integrated framework for disease characterization and intervention, while highlighting physiological uptake, therapy resistance, and CXCR7 compensation as important barriers to translation.
-
15-PGDH Inhibition Restores Muscle Repair
2026-08-09
The 2026 PNAS study identifies 15-PGDH inhibition as a way to improve skeletal muscle regeneration and strength recovery during semaglutide-induced weight loss in obese mice. Its combination strategy preserved semaglutide-associated weight loss while enhancing muscle stem cell activity, regenerated myofiber growth, and postinjury force.
-
Cisapride (R 51619): A Cardiac Risk Compass
2026-08-08
Cisapride (R 51619) offers translational researchers a mechanistically informative challenge compound because it combines nonselective 5-HT4 receptor agonism with hERG potassium channel inhibition. This article shows how to position it within iPSC-derived cardiomyocyte screening, cardiac electrophysiology research, and early cardiac safety decision-making.
-
β-Elemene Inhibits Adipogenesis via AMPK
2026-08-07
The reference study shows that β-Elemene suppresses MDI-induced lipid accumulation and improves glucose handling in differentiated 3T3-L1 adipocytes and an insulin-resistance model. Its main mechanistic contribution is linking these effects to restoration of AMPK pathway activity, while also defining a practical in vitro framework for metabolic research.
-
WY-14643 (Pirinixic Acid): Driving Regenerative Metabolic Re
2026-08-07
Explore how WY-14643 (Pirinixic Acid) uniquely enables advanced investigation into PPARα-driven liver regeneration, metabolic regulation, and inflammation control. This article uncovers mechanistic insights and protocol guidance for metabolic disorder research using this potent APExBIO agonist.
-
Caffeine (1,3,7-trimethylpurine-2,6-dione): Applied Workflow
2026-08-06
Caffeine (1,3,7-trimethylpurine-2,6-dione) is a uniquely versatile tool for dissecting cancer cell line inhibition and metabolic pathway modulation. This article delivers actionable workflows, protocol enhancements, and troubleshooting strategies for maximizing assay reliability with APExBIO’s Caffeine, bridging bench research with translational insight.
-
ABT-199 (Venetoclax): Precision Apoptosis for Hematologic Re
2026-08-06
ABT-199 (Venetoclax) delivers unparalleled selectivity and potency for apoptosis assays in hematologic malignancy research, enabling reliable detection of BCL-2 dependent cell death. This article details applied workflows, troubleshooting strategies, and key innovations that differentiate ABT-199 from less selective Bcl-2 inhibitors.
-
Linoleic Acid–PPARα–TF Axis Drives Tumor Progression in pLEL
2026-08-05
This study uniquely demonstrates that linoleic acid promotes tissue factor (TF) expression via PPARα activation, fueling tumor progression in primary pulmonary lymphoepithelioma-like carcinoma (pLELC). The findings identify the TF pathway as a potential therapeutic target and highlight the importance of lipid metabolism regulation in rare lung cancers.
-
BKT140 (BL-8040) in Oncology: Optimizing CXCR4 Antagonism Wo
2026-08-05
BKT140 (BL-8040) empowers precision oncology research by enabling robust inhibition of CXCR4-mediated tumor progression and efficient hematopoietic stem cell mobilization. Discover advanced protocols, troubleshooting strategies, and data-backed innovations that set this antagonist apart for translational applications.